International Journal of Pharmacy and Pharmaceutical Sciences (Impact Factor: 1.59). 06/2012; 3(4):195-197.

ABSTRACT Atorvastatin calcium (AT) is hypolipidemic agent and Amlodipine besylate (AM) is calcium channel blocker. The combination of both drugs is used in treatment of hypertension. The present communication deals with development of simple, sensitive, rapid and economical method for simultaneous estimation of atorvastatin calcium and amlodipine besylate in combined dosage form. The AT and AM stock solutions are prepared in (50:50 V/V) methanol: water. The method of analysis is derivative spectroscopy to eliminate spectral interference by measuring absorbances at 241nm and 250 nm for AM and AT respectively. The AT and AM are linear in concentration range of 0-14 µg/ml and 0-7 µg/ml respectively. The limit of detection (LOD) and limit of quantitation (LOQ) of AM was 0.29 and 0.75 µg respectively. The limit of detection (LOD) and limit of quantitation (LOQ) of AT was 0.21 and 0.60 µg respectively. The results of analysis were validated by ICH Q2B (R1). The results of recovery studies and precision were found to be within limits. INTRODUCTION Atorvastatin calcium (AT)[ (ßR,dS)-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4[(phenylamino) carbonyl]-1H-pyrrole-1-heptenoic acid calcium salt is a hypolipidemic agent, which inhibits HMG CO-A reductase, enzyme involved in lipid synthesis 1 Amlodipine besylate (AM), [3-ethyl-5-methyl (4RS)-2-[(2-aminoethoxy) methyl]-4-(2-chlorophenyl)-methyl-1-dihydropyridine-3, 5-dicarboxylate benzenesulphonate is a calcium channel blocker, used in hypertension treatment. Both are official in BP and EP

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Caduet tablets are novel prescription drug that combines amlodipine besylate (AM) with atorvastatin calcium (AT). A spectrofluorimetric and an HPLC-fluorescence detection methods were developed for simultaneous determination of both drugs in tablets. In the spectrofluorimetric method, native fluorescence of AM and AT were measured in methanol at 442 and 369 nm upon excitation at 361 and 274 nm, respectively. The emission spectrum of each drug reveals zero value at the emission wavelength of the other drug, thus allowing their simultaneous determination without interference. In the HPLC method, separation of AM and AT was achieved within 8 minutes on a C18 column using acetonitrile:phosphate buffer (0.015 M, pH 3) (45:55, v/v) as the mobile phase. Fluorescence detection was carried out using excitation wavelengths 361 and 274 nm and emission wavelengths 442 and 378 nm for AM and AT, respectively. Excellent linearity was observed. Careful validation proved advantages of the new methods: high sensitivity, accuracy, selectivity and suitability for quality control laboratories.
    Analytical Chemistry Insights 01/2013; 8:107-15.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Two simple, accurate, precise, reproducible UV Spectrophotometric methods have been developed for the simultaneous estimation of Amlodipine Besylate and Indapamide in tablet dosage form. First method employed was Absorption Correction Method which involves direct estimation of Amlodipine Besylate at 360 nm, as at this wavelength Indapamide has zero absorbance and shows no interference. For estimation of Indapamide, corrected absorbance was calculated at 242 nm due to the interference of Amlodipine Besylate at this wavelength. The second method was first order derivative spectrophotometry, wavelengths selected for quantitation were 242 nm for Amlodipine Besylate (zero crossing point for Indapamide) and 238 nm for Indapamide (zero crossing point for Amlodipine Besylate). In both methods linearity was observed in the concentration range of 10-70 μg/ml for Amlodipine Besylate and 2-16 μg/ml for Indapamide.The results of analysis have been validated statistically and by recovery studies. The proposed method was successfully applied for the simultaneous estimation of both drugs in commercial tablet dosage form.
    International Journal of PharmTech Research 08/2012; 4(3):974-4304.


Available from
May 23, 2014